Breaking News, Financial News

Financial Report: Pfizer 2Q

Revenues in the quarter were favorably impacted by $5.4 billion (most of the 58% revenue bump), due to the addition of the legacy Wyeth products.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer 2Q 2Q Revenues: $17.3 billion (+58%) 2Q Earnings: $2.5 billion (+9%) YTD Revenues: $34.1 million (+56%) YTD Earnings: $4.5 billion (-10%) Comments: Revenues in the quarter were favorably impacted by $5.4 billion (most of the 58% revenue bump), due to the addition of the legacy Wyeth products. Biopharmaceutical revenues, which includes Primary Care, Specialty Care, Established Products, Emerging Markets and Oncology, totaled $15.0 billion in the quarter (+49%). Diversified ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters